메뉴 건너뛰기
PharmacoEconomics
Volumn 22, Issue 7, 2004, Pages 477-478
Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C [1]
Author keywords

[No Author keywords available]
Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; PEGINTERFERON ALPHA2A; RIBAVIRIN;
EID: 2942606133     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422070-00005     Document Type: Letter
Times cited : (1)
References (7)
  • 1
    • 1542350630 scopus 로고    scopus 로고
    • NIH consensus Statement on management of hepatitis C: 2002
    • NIH consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002; 19: 1-46
    • (2002) NIH Consens State Sci Statements , vol.19 , pp. 1-46
  • 2
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Sep 26
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26; 347 (13): 975-82
    • (2002) N Engl J Med , vol.347 , Issue.13 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 3
    • 0345416844 scopus 로고    scopus 로고
    • Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
    • Sep
    • Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997 Sep; 26 (3 Suppl. 1): 83S-88S
    • (1997) Hepatology , vol.26 , Issue.3 SUPPL. 1
    • Carithers Jr., R.L.1    Emerson, S.S.2
  • 4
    • 1642413070 scopus 로고    scopus 로고
    • Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    • Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22 (4): 257-65
    • (2004) Pharmacoeconomics , vol.22 , Issue.4 , pp. 257-265
    • Sullivan, S.D.1    Craxi, A.2    Alberti, A.3
  • 5
    • 0033594380 scopus 로고    scopus 로고
    • Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
    • Irish Hepatology Research Group
    • Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33
    • (1999) N Engl J Med , vol.340 , pp. 1228-1233
    • Kenny-Walsh, E.1
  • 6
    • 0042442463 scopus 로고    scopus 로고
    • Hematologic disorders associated with hepatitis C virus infection and their management
    • Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 15: 533-41
    • (2003) Clin Infect Dis , vol.15 , pp. 533-541
    • Dieterich, D.T.1    Spivak, J.L.2
  • 7
    • 0033807659 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of interferon alfa 2a with and without amantadine as initial treatment for chronic hepatitis C
    • Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa 2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835-41
    • (2000) Hepatology , vol.32 , pp. 835-841
    • Zeuzem, S.1    Teuber, G.2    Naumann, U.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.